SEC Comment Letter for Gain Therapeutics, Inc. (GANX) (CIK 0001819411) (GANX) — Jun 4, 2025
Gain Therapeutics, Inc. (GANX) (CIK 0001819411)
Date: June 4, 2025 · CIK: 0001819411 · Accession: 0000000000-25-005890
AI Filing Summary & Sentiment
File numbers found in text: 333-287622
Letter
June 4, 2025 Gene Mack Chief Executive Officer Gain Therapeutics, Inc. 4800 Montgomery Lane, Suite 220 Bethesda, MD 20814 Re:Gain Therapeutics, Inc. Registration Statement on Form S-3 Filed May 28, 2025 File No. 333-287622 Dear Gene Mack: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Daniel Porco
Show Raw Text
June 4, 2025
Gene Mack
Chief Executive Officer
Gain Therapeutics, Inc.
4800 Montgomery Lane, Suite 220
Bethesda, MD 20814
Re:Gain Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 28, 2025
File No. 333-287622
Dear Gene Mack:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Daniel Porco